Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.

Jessie R Nedrow-Byers1, Mohamed Jabbes, Cayla Jewett

  • 1Department of Chemistry,Washington State University, Pullman, Washington 99164-4630, USA.

The Prostate
|June 7, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FOXO3/HMOX1 axis promotes melanoma progression by regulating ferroptosis and immune escape.

Histology and histopathology·2026
Same author

Debulking Combined with Drug-Coated Balloon for the Treatment of Femoropopliteal In-Stent Restenosis: A Systematic Review and Meta-Analysis.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Evolution of pyraclostrobin resistance in Botrytis cinerea from Xinxiang City of China and its targeted management via RNA interference.

Pesticide biochemistry and physiology·2026
Same author

Single Amino Acid Change in the FvHIK1 Protein Associated with Fludioxonil Resistance in <i>Fusarium verticillioides</i>.

Phytopathology·2026
Same author

A Case of Nonpedal Subcorneal Haematoma Mimicking Melanoma.

Acta dermato-venereologica·2026
Same author

FAM72A is associated with lung cancer proliferation and migration via the NF‑κB signaling pathway.

Molecular genetics and genomics : MGG·2026

This study developed a novel SPECT imaging agent, 99mTc-(CO)3-DTPA-CTT-54, targeting prostate-specific membrane antigen (PSMA) in prostate cancer. The agent showed promising uptake and internalization in PSMA-positive cells and tumor xenografts.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Prostate-specific membrane antigen (PSMA) is a key target for prostate cancer diagnostics and therapeutics.
  • Development of targeted imaging agents is crucial for effective prostate cancer management.

Purpose of the Study:

  • To develop and evaluate a novel SPECT imaging agent using a modified phosphoramidate inhibitor (CTT-54) conjugated with a technetium-99m payload (99mTc-(CO)3-DTPA).
  • To assess the in vitro and in vivo performance of the 99mTc-(CO)3-DTPA-CTT-54 conjugate for targeting PSMA-positive prostate cancer cells.

Main Methods:

  • Synthesized an irreversible phosphoramidate inhibitor, CTT-54, and conjugated it with 99mTc-(CO)3-DTPA.
  • Evaluated in vitro: percent uptake, competitive binding, and cellular internalization in PSMA-positive (LNCaP) and negative cells.

More Related Videos

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Experiment Videos

Last Updated: May 21, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

  • Performed preliminary in vivo biodistribution and SPECT imaging studies in LNCaP xenograft models.

    • Main Results:

    • The radiotracer 99mTc-(CO)3-DTPA-CTT-54 demonstrated time-dependent cellular uptake in PSMA-positive LNCaP cells.
    • Rapid internalization of the tracer into LNCaP cells was observed, suggesting PSMA-mediated uptake.
    • Pilot biodistribution studies showed increasing accumulation in LNCaP xenografts and significant clearance from non-target tissues.

    Conclusions:

    • The developed 99mTc-(CO)3-DTPA-CTT-54 conjugate shows proof-of-concept as a PSMA-targeted SPECT imaging agent.
    • Further development of phosphoramidate-based PSMA inhibitor-conjugates is warranted for next-generation prostate cancer imaging.
    • Optimization of the chelate structure may further enhance imaging agent performance.